Posted by Michael Wonder on 13 Feb 2018
Statement from FDA Commissioner Scott Gottlieb on Administration’s request for new FDA funding to promote innovation and broaden patient access through competition
13 February 2018 - Additional resources will help advance initiatives to support novel medical technology and public health priorities such as generic drug development, pharmacy outsourcing and novel domestic manufacturing capabilities.
New scientific opportunities, as well as advances in manufacturing and commerce, give the U.S. Food and Drug Administration new ways to advance our mission to protect and promote public health. Leveraging these opportunities requires us to make investments in regulatory science that can reduce uncertainty for innovators, spur investment in new industries and provide principles for the safe and effective development of new technologies. These same advances also give us new ways to support greater availability and use of generic drugs as a way to promote price competition and patient access.
Toward these goals, the Administration’s newly released budget request provides the FDA with the resources to continue to fund our current programs at consistent levels.
